No Data
Cybin Granted U.S. Patent In Support Of CYB003 Program In MDD
Express News | Cybin Announces Additional U.S. Patent Supporting Its Cyb003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
Cybin (CYBN) Gets a Buy From H.C. Wainwright
Cybin to Participate at the 28th Annual Milken Institute Global Conference
Cybin Announces Additional Strategic Partnership Agreements To Support PARADIGM, Multinational Phase 3 Program Evaluating CYB003
Express News | Cybin - Engages 18 Clinical Sites for Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Mdd